Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

Abstract

In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.

• Authors: A Iravani
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 35 Issue 4 Pg. 750-2 (Apr 1991) ISSN: 0066-4804 [Print] United States
• PMID: 2069382 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cephalosporins
• loracarbef
• Cefaclor

Topics

• Cefaclor (adverse effects, therapeutic use)
• Cephalosporins (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Humans
• Urinary Tract Infections (drug therapy, microbiology)